An observational study in Uterine Hemorrhage, Cardiovascular Diseases and Antithrombotic Drugs, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Shanghai Zhongshan Hospital · Observational
This study aims to investigate uterine bleeding during menstruation in women taking antithrombotic medications after cardiac surgery. It will evaluate the proportion of patients with abnormal bleeding, such as heavy menstrual bleeding and prolonged menstrual periods, identify associated risk factors, and determine the characteristics of high-risk female patients.
160 studies on the registry are indexed under Uterine Hemorrhage; 21 are open to participants now.
This study's planned enrollment of 1,308 is above the median of 122 across 41 observational studies indexed under Uterine Hemorrhage.
Browse Uterine Hemorrhage studies →Shanghai Zhongshan Hospital is the lead sponsor of 648 studies on the registry; 289 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women of childbearing age receiving oral antithrombotic therapy after cardiac surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: antithrombotic drugs
Antithrombotic agents such as anticoagulants (e.g., warfarin, rivaroxaban) and antiplatelet drugs (e.g., aspirin, clopidogrel)
The occurrence of abnormal uterine bleeding in women was assessed using the Pictorial Blood Loss Assessment Chart (PBAC) developed by Higham
The Pictorial Blood Loss Assessment Chart (PBAC) is primarily used to evaluate the occurrence of prolonged menstruation (duration of menstrual bleeding ≥ 9 days) and/or heavy menstrual bleeding (PBAC score ≥ 100) in women.
Time frame: Bleeding at the first menstrual period within two months after discharge
Assessment of Healthcare-Seeking Behaviors for Abnormal Uterine Bleeding Using Custom Items
In this study, custom questionnaire items were used to evaluate the clinical management of patients with AUB, including their healthcare-seeking behaviors (such as physician consultations, inpatient admissions, and emergency care) and specific therapeutic interventions (such as the dose reduction or interruption of oral antithrombotics, and blood transfusions).
Time frame: Within 2 months after discharge
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Nov 2027, 14 months after the start.
Of 16 observational studies under Uterine Hemorrhage, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 14 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.